EGFR and lung carcinoma: For example, EGFR-mutant lung cancer cells that survive treatment with combined EGFR and MEK inhibitors express hallmarks of senescence such as an increase in senescence-associated gene expression signature, senescence-associated b-galactosidase activity (SA-b-Gal), increased secretion of several classical SASP (senescence-associated secretory phenotype) factors, robust induction of p27kip, and punctate H3K9Me3-positive nuclear foci [56].